Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
5.09
+0.10 (2.00%)
At close: Oct 20, 2025, 4:00 PM EDT
5.00
-0.09 (-1.77%)
After-hours: Oct 20, 2025, 6:43 PM EDT
Galectin Therapeutics Employees
Galectin Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 1 or 7.14% compared to the previous year.
Employees
15
Change (1Y)
1
Growth (1Y)
7.14%
Revenue / Employee
n/a
Profits / Employee
-$2,697,133
Market Cap
325.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 1 | 7.14% |
| Dec 31, 2023 | 14 | 2 | 16.67% |
| Dec 31, 2022 | 12 | 3 | 33.33% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 2 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GALT News
- 6 weeks ago - Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - GlobeNewsWire
- 7 months ago - Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - GlobeNewsWire
- 10 months ago - Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? - Benzinga
- 10 months ago - Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH - GlobeNewsWire
- 1 year ago - Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire
- 1 year ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - GlobeNewsWire